Loading company…
Nuvalent develops targeted cancer therapies focused on clinically validated kinase targets.
Founded in 2017 and based in Massachusetts, Nuvalent develops cancer therapies targeting kinases. Its programs include NUV-520, a ROS1-selective inhibitor, and NUV-655, an ALK-selective inhibitor, for advanced non-small cell lung cancer. Founded by James R. Porter and Matthew Shair, the company went public on Nasdaq in July 2021, raising USD 165.75 million through an IPO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in